Damir Begic
About
In The Last Decade
Damir Begic
8 papers receiving 606 citations
Hit Papers
Peers
Comparison fields: 5 of 36
- Hepatology 465
- Oncology 359
- Pathology and Forensic Medicine 154
- Pulmonary and Respiratory Medicine 137
- Epidemiology 117
Countries citing papers authored by Damir Begic
This map shows the geographic impact of Damir Begic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damir Begic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damir Begic more than expected).
Fields of papers citing papers by Damir Begic
This network shows the impact of papers produced by Damir Begic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damir Begic. The network helps show where Damir Begic may publish in the future.
Co-authorship network of co-authors of Damir Begic
This figure shows the co-authorship network connecting the top 25 collaborators of Damir Begic. A scholar is included among the top collaborators of Damir Begic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damir Begic. Damir Begic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | 17 | |
| 3 | 42 | |
| 4 | 26 | |
| 5 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) breakdown → | 497 |
| 6 | 11 | |
| 7 | 0 | |
| 8 | 2 | |
| 9 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.